| 0.709 0.018 (2.6%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.98  |
1-year : | 1.1 |
| Resists | First : | 0.84 |
Second : | 0.94 |
| Pivot price | 0.76 |
|||
| Supports | First : | 0.67 |
Second : | 0.55 |
| MAs | MA(5) : | 0.72 |
MA(20) : | 0.77 |
| MA(100) : | 1.1 |
MA(250) : | 1.17 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.2 |
D(3) : | 14.6 |
| RSI | RSI(14): 39.8  |
|||
| 52-week | High : | 2.48 | Low : | 0.62 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CTXR ] has closed above bottom band by 22.9%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.72 - 0.72 | 0.72 - 0.73 |
| Low: | 0.66 - 0.67 | 0.67 - 0.67 |
| Close: | 0.7 - 0.71 | 0.71 - 0.72 |
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Fri, 13 Feb 2026
Citius Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Fri, 13 Feb 2026
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PR Newswire
Fri, 13 Feb 2026
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PR Newswire
Thu, 12 Feb 2026
Analysts Expect Breakeven For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Before Long - simplywall.st
Wed, 11 Feb 2026
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - PR Newswire
Tue, 23 Dec 2025
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 10.4 (%) |
| Shares Short | 2,920 (K) |
| Shares Short P.Month | 2,630 (K) |
| EPS | -3.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.74 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.5 % |
| Return on Equity (ttm) | -52.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.22 |
| PEG Ratio | 0 |
| Price to Book value | 0.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|